Clinical trials in Alzheimer’s disease often do not include behavioural and psychological symptoms of dementia (BPSD) as a primary outcome. A systematic review of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) in the management of BPSD noted that evidence was limited but concluded that pharmacologic interventions were warranted (Rodda et al. Int Psychogeriatr 2009; 21: 813-824).